On 6 October 2026, the first Life Science VC Day took place in Munich, organised by the Life Science Valley Wachstumsfonds in collaboration with the Life Science Factory and the law firm HEUKING. Under the theme “From Data to Drug: The New Biotech Stack”, the event brought together investors, founders and experts from science and industry.
The focus was on technological developments along the life science value chain – from artificial intelligence and computational drug discovery through automation and enabling technologies to clinical translation. The event offered a platform to explore new research approaches, technological innovations and their potential for advancing the industry.
Start-ups in focus
Six selected companies presented their technological approaches in detailed, technology-focused pitches:
- brainQr Therapeutics
- Stealth Startup
- Onyx Biotech
- UniteLabs
- Medinexify
- 2NA FISH
The presentations offered insights into different areas of innovation in the life sciences and showed how data-driven methods, AI applications and new technology platforms can contribute to the development of innovative solutions. At the same time, they gave the participating investors the opportunity to get to know new approaches and business models and to engage in in-depth discussions with the founders.
Scientific input and a discussion on AI
The programme was complemented by keynote talks from Prof. Dr. Carsten Marr and Prof. Dr. Johan Trygg, who contributed scientific perspectives on current technological developments.
The subsequent panel discussion, moderated by Dr. Stefanie Greifeneder, focused on the role of artificial intelligence in the life sciences. In particular, the panel discussed the fields of application in which AI is already creating concrete added value, the challenges involved in implementing it, and how the real potential of these technologies can be distinguished from inflated expectations.
Exchange at the interface of science and capital
The first Life Science VC Day created a setting for exchange between innovative start-ups, investors and experts from the life science ecosystem. Combining technological insights with scientific input and investment perspectives allowed for a nuanced look at current developments and their significance for the industry.
We would like to thank all participating founders, investors and speakers, as well as our event partners Life Science Factory and HEUKING for their collaboration in designing and delivering the format. We look forward to continuing the dialogue that has begun and to supporting the further development of innovative companies and technologies in the life science sector.